Markets

Jazz Pharmaceuticals Presents Data From Its Phase 3 HERIZON-GEA-01 Study Of Ziihera In Combination With Chemotherapy At ESMO Congress 2026 To Treat Patients With HER2-Positive Locally Advanced Or Metastatic Gastroesophageal Adenocarcinoma

Oct 23, 2026 · 10:20 AM ET· updated 56m ago

HJazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced updated overall survival (OS) results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera® (zanidatamab-hrii) in combination with chemotherapy, with or

Why It Matters

Jazz Pharmaceuticals shared new test results for a cancer medicine called Ziihera. When a company shows study data, investors watch to see if the medicine works well and might get approved.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

JAZZ212.40

-2.25 (-1.05%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.